Safety and Tolerability of Yaq-001 in Patients With Cirrhosis

Exclusion Criteria

• •1. Refusal or inability (lack of capacity) to give informed consent
• •2. Prohibited medication within 4 weeks before the start of the study treatment: all oral antibiotics, immunosuppressants, long acting benzodiazepines or barbiturates and antiviral medication
• •3. Change in dose of proton pump inhibitor therapy within 4 weeks before the start of the study treatment
• •4. Patients with once daily medications in which orocaecal transit time is greater than 10 hours
• •5. Patients requiring medication in which the dosing schedule is three times per day or greater
• •6. Antiviral therapy for hepatitis C within 3 months prior to screening
• •7. Hospital admission for liver-related indication for at least 4 weeks (except paracentesis)
• •8. BMI \> 35 or BMI \< 18
• •9. Clostridium Difficile diarrhoea within 4 weeks before the start of the study treatment
• •10. Uncontrolled infection (chronic viral hepatitis is not an exclusion criterion)
• •11. Human immunodeficiency virus
• •12. Presence of a transjugular intrahepatic portosystemic shunt (TIPSS)
• •13. Participation in any clinical study of an investigational medicinal product within 30 days of five half-lives of the investigational product, whichever is longer
• •14. Presence of clinically relevant cardiovascular, pulmonary, gastro-intestinal, renal, hepatic, metabolic, haematological, neurological, psychiatric, systemic, ocular, gynaecologic or any acute infection disease or signs of acute illness that, in the opinion of the investigator, might compromise the patient's safe participation in the trial and/or results in a WHO performance status of 2 or more.
• •15. Presence of the history of cancer within the past 5 years with exception of hepatocellular carcinoma within Milan criteria, adequately treated localised basal cell carcinoma of the skin, in situ cervical carcinoma or solid malignancy surgical excised in total without recurrence for five years.
• •16. Women of child bearing potential. Only postmenopausal women or with surgical sterilization will be included.